In the event of a conflict between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. Plan documents include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents.

In the event of a conflict between a Clinical Payment and Coding Policy and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern.

Providers are responsible for accurately, completely, and legibly documenting the services performed including any preoperative workup. The billing office is expected to submit claims for services rendered using valid codes from Health Insurance Portability and Accountability Act (HIPAA) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (UB) Editor, American Medical Association (AMA), Current Procedural Terminology (CPT®), CPT® Assistant, Healthcare Common Procedure Coding System (HCPCS), National Drug Codes (NDC), Diagnosis Related Group (DRG) guidelines, Centers for Medicare and Medicaid Services (CMS) National Correct Coding Initiative (CCI) Policy Manual, CCI table edits and other CMS guidelines. Claims are subject to the code auditing protocols for services/procedures billed.

## **Preventive Services Policy**

**Policy Number: CPCP006** 

Version 1.0

Enterprise Clinical Payment and Coding Policy Committee Approval Date: 12/27/2018

**Effective Date: 02/01/2019** 

## **Description**

Section 2713 of the Affordable Care Act mandates that private health plans provide coverage of preventive services issued by the following agencies: The United States Preventive Services Task Force (USPSTF), the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), and the Health Resources and Service Administration (HRSA) with respect to women's guidelines and guidelines for infants, children, and adolescents. These services are available at no cost-share when obtained by a member covered under a non-grandfathered plan. This applies to members belonging to individual, small group, large group, and self-insured plans. There is no copay, deductible or coinsurance, even if the individual or family deductible or out-of-pocket maximum has not been met as long as the member utilizes a provider in the plan's network.

The Patient Protection and Affordable Care Act of 2010 does not mandate that preventive services be covered at no member cost-share when obtained out-of-network. Members that obtain preventive services out of their network will be subject to copay, deductible, and coinsurance.

Grandfathered plans are plans that have been in existence prior to March 23, 2010 and are exempt from the requirement of providing preventive services at no member cost share. Grandfathered plans have the opportunity to elect providing coverage of preventive services at no member cost share but are not required to do so.

The following acronyms have been utilized throughout this reimbursement policy

United States Preventive Services Task Force

ACIP: Advisory Committee on Immunization Practices
CDC: Centers for Disease Control and Prevention
FDA: United States Food and Drug Administration
HRSA: Health Resources and Services Administration
PPACA: Patient Protection and Affordable Care Act of 2010

**USPSTF:** 

The United States Preventive Services Task Force (USPSTF) applies a letter grade for each of the recommendations that are released. The grade definitions for USPSTF recommendations released after July 2012 are as follows <a href="https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions">https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions</a>

Following the recommendation of the United States Preventive Services Task Force coverage of Grade "A" and "B" recommendations is provided at no member cost share for members with a non-grandfathered health plan. The United States Preventive Services Task Force published recommendations can be found at https://www.uspreventiveservicestaskforce.org/BrowseRec/Index

Grade	Definition
Α	The USPSTF recommends the service. There is high
_ ^	certainty that the net benefit is substantial.
В	The USPSTF recommends the service. There is high
	certainty that the net benefit is moderate or there is
	moderate certainty that the net benefit is moderate to
	substantial.
	The USPSTF recommends selectively offering or providing
	this service to individual patients based on professional
	judgment and patient preferences. There is at least
	moderate certainty that the net benefit is small.
D	The USPSTF recommends against the service. There is
	moderate or high certainty that the service has no net
	benefit or that the harms outweigh the benefits.
1	The USPSTF concludes that the current evidence is
•	insufficient to assess the balance of benefits and harms of
	the service. Evidence is lacking, of poor quality, or
	conflicting, and the balance of benefits and harms cannot
	be determined.

The Advisory Committee on Immunization Practices (ACIP) publishes recommendations on the safe utilization of vaccines. ACIP's recommendations include immunization schedules for children and adolescents as well as adults which can be found at

https://www.cdc.gov/vaccines/schedules/hcp/index.html . Travel Immunizations such as, but not limited to, Japanese Encephalitis, Typhoid, Yellow Fever, and Small Pox are excluded from Preventive Service coverage. Other excluded vaccinations include Anthrax, Bacille Calmette Guerin for Tuberculosis (BCG), and Rabies which are not required by the Patient Protection and Affordable Care Act of 2010. Immunizations should be administered in accordance with the ACIP Recommended Child and Adult Immunization Schedules or in accordance with state law or regulations.

The Health Resources and Services Administration (HRSA) releases Women's Preventive Services guidelines that are aimed at improving women's health by recommending certain preventive services that should be obtained in the clinical setting. HRSA's list of recommendations can be obtained at https://www.hrsa.gov/womensguidelines2016/index.html

The Health Resources and Services Administration (HRSA) endorses preventive guidelines established by the American Academy of Pediatrics for the health and well-being of infants, children, and adolescents. These recommendations are referred to as Bright Futures and the comprehensive list of Bright Future's recommendations can be found at

https://www.aap.org/en-us/Documents/practicet\_periodicity\_AllVisits.pdf

#### **Reimbursement Information:**

Preventive care or preventive medicine refers to measures or services taken to promote health and early detection/prevention of disease(s) and injuries rather than treating them and/or curing them. Preventive care may include examinations and screening tests tailored to an individual's age, health, and family history.

Certain preventive care services may be considered eligible for coverage under the member's benefit plan as required by the Affordable Care Act and/or an applicable state mandate. In general, these services include, but are not limited to, screenings, immunizations, and other types of care as recommended by the United States Federal Government.

These services are not subject to application of cost-sharing such as co-payments, co-insurance or deductibles when they are considered eligible for coverage and are provided by a network provider. In order for preventive claims to process at the preventive level with no member cost share, the claim must include a preventive diagnosis code, a preventive procedure code, meet medical policy review criteria, and fall within the guidelines issued by the USPSTF, ACIP, HRSA, or Bright Futures.

Health care providers (facilities, physicians and other health care professionals) are expected to exercise independent medical judgement in providing care to patients. This Preventive Services Reimbursement policy is not intended to impact care decisions or medical practice. Providers are responsible for accurately, completely, and legibly documenting the services performed. The billing office is expected to submit claims for services rendered using valid codes from HIPAA-approved code sets.

The following grid provides a list of the recommendations released by the USPSTF, ACIP, HRSA, or Bright Futures along with the corresponding procedure codes and diagnosis codes deemed to be preventive.

### **USPSTF Recommendations:**

Service:	Procedure	Additional
	Code(s):	Reimbursement Criteria:
Abdominal Aortic Aneurysm Screening  USPSTF "B" Recommendation June 2014  The USPSTF recommends one-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men ages 65 to 75 years who have ever smoked.	76706	Payable with a diagnosis code in Diagnosis List 1
Abnormal Blood Glucose and Type 2 Diabetes Mellitus Screening  USPSTF "B" Recommendation October 2015 The USPSTF recommends screening for abnormal blood glucose as part of	82947, 82948, 82950, 82951, 83036, 82952	Payable with a diagnosis code in Diagnosis List 1
cardiovascular risk assessment in adults aged 40 to 70 years who are overweight or obese. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity.		
Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions	99385, 99386, 99387, 99395, 99396, 99397, 99408, 99409, G0396, G0397,	
USPSTF "B" Recommendation November 2018	G0442, G0443	
The USPSTF recommends screening for unhealthy alcohol use in primary care settings for adults 18 years or older, including		
pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to		
reduce unhealthy alcohol use.  Aspirin Use to Prevent Cardiovascular		For details about pharmacy
Disease and Colorectal Cancer Preventive Medication		benefit coverage, contact the number on the patient's BCBS member card. A patient's
<u>USPSTF "B" Recommendation April 2016</u> The USPSTF recommends initiating low-dose		pharmacy benefit may be

aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.		managed by a company other than BCBS.  Prescription required  Coverage includes 81 mg dosage for generics
Asymptomatic Bacteriuria in Adults Screening  USPSTF "A" Recommendation July 2008 The USPSTF recommends screening for asymptomatic bacteriuria with urine culture for pregnant women at 12 to 16 weeks' gestation or at their first prenatal visit, if later.	81007, 87086, 87088	
BRCA-Related Cancer Risk Assessment, Genetic Testing  USPSTF "B" Recommendation December 2013 The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing.	81212, 81215, 81216, 81217, 81162, 81163, 81164, 81165, 81166, 81167, 96040, 99385, 99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, G0463, S0265	These services are subject to Medical Policy and prior authorization may be required  Procedure codes 81212, 81215-81217, and 81162-81167 are reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3, Z80.41, Z85.3, Z85.43  Procedure code 96040 is reimbursable as preventive when submitted with one of the following primary diagnosis codes: Z80.3 or Z80.41  All other procedure codes for BRCA are payable with a diagnosis in Diagnosis List 1
Breast Cancer Medications for Risk Reduction  USPSTF "B" Recommendations September 2013 The USPSTF recommends that clinicians engage in shared, informed decision making		For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.

Chlamydia Screening	86631, 86632, 87110, 87270, 87320, 87490,	Payable with a diagnosis code in Diagnosis List 1
USPSTF "A" Recommendation August 2018 The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting).  Refer also to HRSA's 'Cervical Cancer Screening' recommendation	99385, 99386, 99387, 99395, 99396,99397  G0101, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88155, 88164, 88165, 88166, 88167, 88174, 88175, G0123, G0124, hearG0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091, 87623, 87624, 87625, S0610, S0612, 0500T	Payable with a diagnosis code in Diagnosis List 1
Breastfeeding Primary Care Interventions  USPSTF "B" Recommendation October 2016 The USPSTF recommends providing interventions during pregnancy and after birth to support breastfeeding.  Refer also to HRSA's 'Breastfeeding Services and Supplies' recommendation	99401, 99402, 99403, 99404, 99411, 99412 A4281, A4282, A4283, A4284, A4285, A4286, E0602, E0603, E0604, S9443	Electric breast pumps limited to one per benefit period. Hospital Grade breast pumps are limited to rental only.  Additional reimbursement information available within the "Breastfeeding Equipment and Supplies"
with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene.  Breast Cancer Screening  USPSTF "B" Recommendation January 2016 The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.  Refer also to HRSA's 'Breast Cancer Screening for Women at Average Risk' recommendation	77061, 77062, 77063, 77067	Prescription required.  Generic drugs Tamoxifen and Raloxifene are reimbursable at the preventive level for ages 35 and over  Payable with a diagnosis code in Diagnosis List 1

USPSTF "B" Recommendations September 2014  The USPSTF recommends screening for chlamydia in sexually active women age 24 years and younger and in older women who are at increased risk for infection.	87491, 87492, 87801, 87810	
USPSTF "A" Recommendation June 2016 The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.  The risks and benefits of different screening methods vary.	82270, 82274, G0328, 44388, 44389,44392, 44394, 44401, 44404, 45378,45380, 45381,45384, 45385,45388, G0105, G0106, G0120, G0121, G0122,45330, 45331, 45333,45335, 45338,45346, 74263, 88304, G0104, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, S0285, 00812, 00813 81528	Certain colorectal cancer screening services may be subject to medical policy criteria and may require prior authorization  Modifier 33 or PT may be applied  Payable with a diagnosis in Diagnosis List 1  In the instance that a polyp is removed during a preventive colonoscopy, the colonoscopy as well as the removal of the polyp and the labs and services related to the colonoscopy are reimbursable at the preventive level.  Sedation procedure codes 99152, 99153, 99156, 99157, and G0500 will process at the preventive level when billed with a diagnosis of Z12.11 or Z12.12  Procedure code 74263 is reimbursable at the preventive level when billed with one of the following three diagnosis codes: Z00.00, Z12.11, Z12.12
Congenital Hypothyroidism Screening	84436, 84437, 84443, 99381, S3620	
USPSTF "A" Recommendation March 2008 The USPSTF recommends screening for congenital hypothyroidism in newborns.		
Dental Caries in Children from Birth Through Age 5 Years Screening  USPSTF "B" Recommendation May 2014 The USPSTF recommends that primary care	99188	Prescription required for both over-the-counter (OTC) and prescription medications

clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in		
fluoride.		
USPSTF "B" Recommendation May 2014 The USPSTF recommends that primary care		
clinicians apply fluoride varnish to the primary teeth of all infants and children		
starting at the age of primary tooth eruption.		
Depression Screening Adults	99385, 99386, 99387, 99395, 99396, 99397,	Payable with a diagnosis code in Diagnosis List 1
USPSTF "B" Recommendation January 2016	96160, 96161, G0444	
The USPSTF recommends screening for		
depression in the general adult population, including pregnant and postpartum women.		
Screening should be implemented with		
adequate systems in place to ensure accurate		
diagnosis, effective treatment, and appropriate follow-up.		
·		
Depression in Children and Adolescents Screening	99384, 99385, 99394, 99395, 96127, G0444	Payable with a diagnosis in
Screening	99393, 90127, 00444	Diagnosis List 1
USPSTF "B" Recommendation February 2016		Effective 1/1/2019, Procedure
The USPSTF recommends screening for major		code 96127 is only reimbursable
depressive disorder (MDD) in adolescents		Lat the proventive level when hilled L
depressive disorder (MDD) in adolescents aged 12 to 18 years. Screening should be		at the preventive level when billed with a diagnosis of Z00.129,
aged 12 to 18 years. Screening should be implemented with adequate systems in place		at the preventive level when billed with a diagnosis of Z00.129, Z13.41, or Z13.42
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective		with a diagnosis of Z00.129,
aged 12 to 18 years. Screening should be implemented with adequate systems in place		with a diagnosis of Z00.129,
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression'		with a diagnosis of Z00.129,
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.		with a diagnosis of Z00.129,
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation  Falls Prevention in Community Dwelling	97110, 97112, 97116,	with a diagnosis of Z00.129,
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation	97150, 97161, 97162,	with a diagnosis of Z00.129, Z13.41, or Z13.42  Prescription required
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation  Falls Prevention in Community Dwelling Older Adults: Interventions	97150, 97161, 97162, 97163, 97164, 97165,	with a diagnosis of Z00.129, Z13.41, or Z13.42  Prescription required  Over the counter (OTC) Vitamin D
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation  Falls Prevention in Community Dwelling	97150, 97161, 97162,	with a diagnosis of Z00.129, Z13.41, or Z13.42  Prescription required
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation  Falls Prevention in Community Dwelling Older Adults: Interventions  USPSTF "B" Recommendation April 2018 The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults	97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168,	with a diagnosis of Z00.129, Z13.41, or Z13.42  Prescription required  Over the counter (OTC) Vitamin D (400-1000 I.U.) only.  Procedure codes 97110, 97112,
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation  Falls Prevention in Community Dwelling Older Adults: Interventions  USPSTF "B" Recommendation April 2018 The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults aged 65 years or older who are at increased	97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168,	with a diagnosis of Z00.129, Z13.41, or Z13.42  Prescription required  Over the counter (OTC) Vitamin D (400-1000 I.U.) only.  Procedure codes 97110, 97112, 97116, 97150, 97161, 97162,
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation  Falls Prevention in Community Dwelling Older Adults: Interventions  USPSTF "B" Recommendation April 2018 The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults	97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168,	with a diagnosis of Z00.129, Z13.41, or Z13.42  Prescription required  Over the counter (OTC) Vitamin D (400-1000 I.U.) only.  Procedure codes 97110, 97112,
aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.  Refer also to Bright Futures 'Depression Screening' recommendation  Falls Prevention in Community Dwelling Older Adults: Interventions  USPSTF "B" Recommendation April 2018 The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults aged 65 years or older who are at increased	97150, 97161, 97162, 97163, 97164, 97165, 97166, 97167, 97168,	with a diagnosis of Z00.129, Z13.41, or Z13.42  Prescription required  Over the counter (OTC) Vitamin D (400-1000 I.U.) only.  Procedure codes 97110, 97112, 97116, 97150, 97161, 97162, 97163, 97164, 97165, 97166,

Folic Acid for the Prevention of Neural Tube Defects: Preventive Medication  USPSTF "A" Recommendation January 2017 The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid.  Gestational Diabetes Mellitus Screening	36415, 82947, 82948,	Prescription required  Over-the-counter (OTC) only  Payable with a pregnancy
USPSTF "B" Recommendation January 2014 The USPSTF recommends screening for gestational diabetes mellitus (GDM) in asymptomatic pregnant women after 24 weeks of gestation.  Refer also to HRSA's 'Gestational Diabetes' recommendation	82950, 82951, 82952, 83036	diagnosis
Gonorrhea Screening  USPSTF "B" Recommendation September 2014 The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.	87801, 87590, 87591, 87592, 87850	Payable with a diagnosis code in Diagnosis List 1
Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults with Cardiovascular Risk Factors: Behavioral Counseling  USPSTF "B" Recommendation August 2014 The USPSTF recommends offering or referring adults who are overweight or obese and have additional cardiovascular disease (CVD) risk factors to intensive behavioral counseling interventions to promote a healthful diet and physical activity for CVD prevention.	99385, 99386, 99387, 99395, 99396, 99397, G0438, G0439, G0446, S9451, S9452, S9470, 97802, 97803, 97804, G0270, G0271, 99078, 99401, 99402, 99403, 99404, 99411, 99412, G0473	
Hepatitis B in Pregnant Women Screening  USPSTF "A" Recommendation June 2009  The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit.	80055, 86706, 87340, 87341, 80074, 80076, G0499, 36415	Payable with a diagnosis code in Diagnosis List 1

Hepatitis B Virus Infection Screening  USPSTF "B" Recommendation May 2014  The USPSTF recommends screening for hepatitis B virus (HBV) infection in persons at high risk for infection.	80055, 86706, 87340, 87341, 80074, 80076	Payable with a diagnosis code in Diagnosis List 1
Hepatitis C Screening  USPSTF "B" Recommendation June 2013 The USPSTF recommends screening for hepatitis C virus (HCV) infection in persons at high risk for infection. The USPSTF also recommends offering 1-time screening for HCV infection to adults born between 1945 and 1965.	86803, 86804, G0472	Payable with a diagnosis code in Diagnosis List 1
High Blood Pressure in Adults Screening  USPSTF "A" Recommendation October 2015 The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. The USPSTF recommends obtaining measurements outside of the clinical setting for diagnostic confirmation before starting treatment.	93784, 93786, 93788, 93790, 99385, 99386, 99387, 99395, 99396, 99397	Procedure codes 93784, 93786, 93788, and 93790 are reimbursable at the preventive level when billed with one of the following diagnosis codes: R03.0, R03.1, Z01.30, Z01.31
Human Immunodeficiency Virus (HIV) Infection Screening for Non-Pregnant Adolescents and Adults  USPSTF "A" Recommendation April 2013 The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk should also be screened.  Refer also to HRSA's 'HIV Screening and Counseling' recommendation  Refer also to Bright Future's 'STI/HIV Screening' recommendation	87806, 87389, 87390, 87391, G0432, G0433, G0435	Payable with a diagnosis code in Diagnosis List 1

Human Immunodeficiency Virus (HIV) Infection Screening for Pregnant Women  USPSTF "A" Recommendation April 2013 The USPSTF recommends that clinicians screen all pregnant women for HIV, including those who present in labor who are untested and whose HIV status is unknown.  Refer also to HRSA's 'HIV Screening and Counseling' recommendation  Refer also to Bright Future's 'STI/HIV Screening' recommendation	36415, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475	Payable with a pregnancy diagnosis or diagnosis from Diagnosis List 1
Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults Screening  USPSTF "B" Recommendation October 2018  The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians screen for intimate partner violence in women of reproductive age and provide or refer women who screen positive to ongoing support services.  Latent Tuberculosis Infection Screening	99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99384, 99385, 99386,99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, S0610, S0612, S0613	Payable with a diagnosis code in
USPSTF "B" Recommendation September 2016 The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.		Diagnosis List 1
Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality from Preeclampsia: Preventive Medication  USPSTF "B" Recommendation September 2014  The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.		Coverage includes 81 mg dosage for generics  For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.

USPSTF "B" Recommendation December 2013 The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.	G0296, G0297	Subject to medical policy criteria and may require preauthorization  Procedure code G0297 is reimbursable at the preventive level if it meets medical policy criteria and is billed with one of the following diagnosis codes: F17.200, F17.201, F17.210, F17.211, F17.220, F17.221, F17.290, F17.291, Z12.2, Z87.891
Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions  USPSTF "B" Recommendation September 2018 The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive, multicomponent behavioral interventions.	97802, 97803, 97804, 99385, 99386, 99387, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, 99078, G0447, G0473	
Obesity in Children and Adolescents Screening  USPSTF "B" Recommendation June 2017 The USPSTF recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer them or refer them to comprehensive, intensive behavioral interventions to promote improvement in weight status.  Ocular Prophylaxis for Gonococcal	97802, 97803, 99383, 99384, 99385, 99393, 99401, 99402, 99403, 99404, 99411, 99412, G0446, G0447, G0473	When billed under inpatient
Ophthalmia Neonatorum Preventive Medication  USPSTF "A" Recommendation July 2011		medical

The USPSTF recommends prophylactic ocular topical medication for all newborns for the prevention of gonococcal ophthalmia neonatorum.		
USPSTF "B" Recommendation June 2018 The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.  The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in posteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.	76977, 77078, 77080, 77081, 78350, 78351, G0130	Payable with a diagnosis code in Diagnosis List 1
Phenylketonuria in Newborns Screening  USPSTF "A" Recommendation March 2008  The USPSTF recommends screening for phenylketonuria in newborns.	84030, 99381, S3620	Procedure codes 84030 and S3620 reimbursable at the preventive level for children 0-90 days old
Preeclampsia Screening  USPSTF "B" Recommendation April 2017 The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.		Preeclampsia screening is done through routine blood pressure measurements
Rh(D) Incompatibility Screening  USPSTF "A" Recommendation February 2004 The USPSTF strongly recommends Rh(D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy-related care.  USPSTF "B" Recommendation February 2004 The USPSTF recommends repeated Rh(D) antibody testing for all unsensitized Rh(D)- negative women at 24 to 28 weeks' gestation,	80055, 86850, 86870, 86900, 86901, 36415	

unless the biological father is known to be		
Rh(D)-negative.		
Sexually Transmitted Infections Behavioral Counseling  USPSTF "B" Recommendation September 2014  The USPSTF recommends intensive behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs).  Refer also to HRSA's 'Sexually Transmitted Infections Counseling' recommendation	99384, 99385, 99386, 99387, 99394, 99395, 99396, 99397, 99401, 99402, 99403, 99404, 99411, 99412, G0445	
Sickle Cell Disease (Hemoglobinopathies) in Newborns Screening  USPSTF "A" Recommendation September 2007 The USPSTF recommends screening for sickle cell disease in newborns.	83020, 83021, 83030, 83033, 83051, 85004, 85013, 85014, 85018, 85025, 85027, 99381, G0306, G0307, S3620, S3850	
Skin Cancer Counseling  USPSTF "B" Recommendation March 2018 The USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer.	There are no procedure codes specific to skin cancer counseling.	
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults Preventive Medication  USPSTF "B" Recommendation November 2016 The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (i.e., symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and	80061, 82465, 83700, 83718, 83719, 83721, 84478	Prescription required  Ages 40-75 only  Lovastatin 20mg, 40mg  Pravastatin 10mg, 20mg, 40mg,  80mg  For details about pharmacy benefit coverage, contact the

mortality when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1 or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a calculated 10-year risk of a cardiovascular event of 10% or greater.  Identification of dyslipidemia and calculation		number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.
of 10-year CVD event risk requires universal lipids screening in adults aged 40 to 75 years.		
Syphilis Infection in Nonpregnant Adults and Adolescents Screening	86592, 86780, 0065U	
USPSTF "A" Recommendation June 2016 The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.		
Syphilis Infection in Pregnant Women Screening	80055, 86592, 86593,0065U, 36415	
<u>USPSTF "A" Recommendation September</u> <u>2018</u>		
The USPSTF recommends early screening for syphilis infection in all pregnant women.		
Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions  USPSTF "A" Recommendation September	99401, 99402, 99403, 99404, 99406, 99407, G9016, S9453	Two 90-day treatment regimens per benefit period. The 90-day treatments are at the discretion of the provider working with the member
2015 The USPSTF recommends that clinicians ask		Prescription required for all
all adults about tobacco use, advise them to stop using tobacco, and provide behavioral		pharmacotherapy interventions
interventions and U.S. Food and Drug Administration (FDA)—approved pharmacotherapy for cessation to adults who		bupropion tan ER 150 mg tablets Chantix Nicrotrol Inhaler
use tobacco. <u>USPSTF "A" Recommendation September</u>		Nicotrol NS Nicotine Transdermal Kits Generic gum and lozenges
2015 The USPSTF recommends that clinicians ask		(nicotine polacrilex 2 mg, 4 mg)
all pregnant women about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation		For details about pharmacy benefit coverage, contact the number on the patient's BCBS
to pregnant women who use tobacco.		member card. A patient's

		pharmacy benefit may be managed by a company other than BCBS.
Tobacco Use in Children and Adolescents	99401, 99402, 99403,	Refer to Preventive Services
Primary Care Interventions	99404, 99406, 99407,	Recommendation for Tobacco
-	G9016, S9453	Smoking Cessation in Adults,
USPSTF "B" Recommendation August 2013		Including Pregnant Women:
The USPSTF recommends that primary care		Behavioral and Pharmacotherapy
clinicians provide interventions, including		Interventions
education or brief counseling, to prevent		
initiation of tobacco use among school-aged		
children and adolescents.		
Vision Screening in Children	99172, 99173, 0333T	
USPSTF "B" Recommendation September		
2017		
The USPSTF recommends vision screening at		
least once in all children aged 3 to 5 years to		
detect amblyopia or its risk factors.		

## **HRSA Recommendations:**

Service:	Procedure	Additional Reimbursement Criteria:
	Code(s):	
Breast Cancer Screening for	77061, 77062, 77063,	Payable with a diagnosis code in Diagnosis List 1
Women at Average Risk	77065, 77066, 77067,	
	G0279	
HRSA Recommendation		
December 2016		
The Women's Preventive		
Services Initiative		
recommends that average-		
risk women initiate		
mammography screening no		
earlier than age 40 and no		
later than age 50. Screening		
mammography should occur		
at least biennially and as		
frequently as annually.		

Screening should continue through at least age 74 and age alone should not be the basis to discontinue screening. These screening recommendations are for women at average risk of breast cancer. Women at increased risk should also undergo periodic mammography screening, however, recommendations for additional services are beyond the scope of this recommendation  Refer also to USPSTF's 'Breast Cancer Screening' recommendation  Breastfeeding Services and Supplies  HRSA Recommendation  December 2016 The Women's Preventive	E0602, E0603, E0604, A4281, A4282, A4283, A4284, A4285, A4286, S9443, 99401, 99402, 99403, 99404, 99411, 99412,	Electric breast pumps limited to one per benefit period. Hospital Grade breast pumps are limited to rental only.  Additional reimbursement information available within the "Breastfeeding Equipment and
lactation support services (including counseling, education, and breastfeeding equipment and supplies) during the antenatal, perinatal, and the postpartum period to ensure the successful initiation and maintenance of breastfeeding.		
Refer also to USPSTF's 'Breastfeeding Primary Care Interventions' recommendation		
Cervical Cancer Screening	99385, 99386, 99387, 99395, 99396, 99397,	Payable with a diagnosis code in Diagnosis List 1
HRSA Recommendation December 2016 The Women's Preventive	G0101, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153,	

Services Initiative 88155, 88164, 88165, recommends cervical cancer 88166, 88167, 88174, screening for average-risk 88175, G0123, women aged 21 to 65 years. G0124, G0141, For women aged 21 to 29 G0143, G0144, years, the Women's G0145, G0147, **Preventive Services Initiative** G0148, P3000, P3001, recommends cervical cancer Q0091, 87623, 87624, screening using cervical S0610, S0612 cytology (Pap test) every 3 years. Cotesting with cytology and human papillomavirus testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with cytology and human papillomavirus testing every 5 years or cytology alone every 3 years. Women who are at average risk should not be screened more than once every 3 years. Refer also to USPSTF 'Cervical Cancer Screening' recommendation A4268, A4269, 57170, **Contraceptive Methods and** Contraception methods that require a prescription Counseling 74740, 96372, 11976, may be covered under the patient's medical or 11981, 11982, 11983, pharmacy benefit. For details about pharmacy HRSA Recommendation 58300, 58301, A4261, benefit coverage for contraception, contact the A4264, A4266, S4981, number on the patient's BCBS member card. A December 2016 S4989, J1050, J7297, patient's pharmacy benefit may be managed by a The Women's Preventive J7298, J7300, J7301, company other than BCBS. **Services Initiative** J7303, J7304, J7306, recommends that adolescent J7307, 58600, 58605, Visits pertaining to contraceptive counseling, and adult women have initiation of contraceptive use, and follow-up care 58611, 58615, 58661 access to the full range of female-controlled 58565, 58670, 58671, may also apply to procedure codes under HRSA's 58340, J7296 'Well-Woman' recommendation contraceptives to prevent unintended pregnancy and Procedure code 58340 reimbursable at the improve birth outcomes. preventive level only when accompanied with Contraceptive care should include contraceptive modifier 33 or one of the following diagnosis codes: Z30.2, Z30.40, Z30.42, Z30.49, Z98.51, counseling, initiation of contraceptive use, and Procedure codes 11981, 11982, and 11983 (are follow-up care (e.g.,

management, and evaluation as well as changes to and removal or discontinuation of the contraceptive method). The Women's **Preventive Services Initiative** recommends that the full range of female-controlled U.S. Food and Drug Administration-approved contraceptive methods, effective family planning practices, and sterilization procedures be available as part of contraceptive care. The full range of contraceptive methods for women currently identified by the U.S. Food and Drug Administration include: (1) sterilization surgery for women, (2) surgical sterilization via implant for women, (3) implantable rods, (4) copper intrauterine devices, (5) intrauterine devices with progestin (all durations and doses), (6) the shot or injection, (7) oral contraceptives (combined pill), 8) oral contraceptives (progestin only, and), (9) oral contraceptives (extended or continuous use), (10) the contraceptive patch, (11) vaginal contraceptive rings, (12) diaphragms, (13) contraceptive sponges, (14) cervical caps, (15) female condoms, (16) spermicides, and (17) emergency contraception (levonorgestrel), and (18) emergency contraception (ulipristal acetate), and additional methods as identified by the FDA. Additionally, instruction in

covered only when FDA approved contraceptive implant insertion or removal are performed) are reimbursable at the preventive level when billed with one of the following diagnosis codes: Z30.013, Z30.014, Z30.017, Z30.018, Z30.19, Z30.09, Z30.40, Z30.42, Z30.430, Z30.432, Z30.433, Z30.46, Z30.49, Z30.8, Z30.9

Procedure code 58661 reimbursable at the preventive level with a diagnosis of Z30.2

For the list of contraceptive methods that may be covered, visit your health plan website.

	1	
fertility awareness-based		
methods, including the		
lactation amenorrhea		
method, although less		
effective, should be provided		
for women desiring an		
alternative method.		
alternative method.		
Diabetes Mellitus Screening	82947, 82948, 82950,	Payable with a diagnosis code in Diagnosis List 1
after Pregnancy	82951, 83036	r ayable with a diagnosis code in Diagnosis List 1
arter Fregulaticy	62931, 63030	
HRSA Recommendation		
December 2017		
The Women's Preventive		
Services Initiative		
recommends women with a		
history of gestational		
diabetes mellitus (GDM) who		
are not currently pregnant		
and who have not been		
previously diagnosed with		
type 2 diabetes mellitus		
should be screened for		
diabetes mellitus.		
Gestational Diabetes	82947, 82948, 82950,	Payable with a pregnancy diagnosis
Gestational Diabetes	82947, 82948, 82950, 82951, 83036	Payable with a pregnancy diagnosis
	82947, 82948, 82950, 82951, 83036	Payable with a pregnancy diagnosis
HRSA Recommendation		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016  The Women's Preventive		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening		Payable with a pregnancy diagnosis
HRSA Recommendation  December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose challenge test (followed by a		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose challenge test (followed by a 3-hour 100- g oral glucose		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose challenge test (followed by a 3-hour 100- g oral glucose tolerance test if results on the initial oral glucose		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose challenge test (followed by a 3-hour 100- g oral glucose tolerance test if results on the initial oral glucose challenge test are abnormal)		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose challenge test (followed by a 3-hour 100- g oral glucose tolerance test if results on the initial oral glucose challenge test are abnormal) is preferred because of its		Payable with a pregnancy diagnosis
HRSA Recommendation December 2016 The Women's Preventive Services Initiative recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation (preferably between 24 and 28 weeks of gestation) in order to prevent adverse birth outcomes. Screening with a 50-g oral glucose challenge test (followed by a 3-hour 100- g oral glucose tolerance test if results on the initial oral glucose challenge test are abnormal)		Payable with a pregnancy diagnosis

Preventive Services Initiative		
suggests that women with		
risk factors for diabetes		
mellitus be screened for		
preexisting diabetes before		
24 weeks of gestation—		
ideally at the first prenatal		
visit, based on current		
clinical best practices		
oour best pressions		
Refer also to USPSTF's		
'Gestational Diabetes		
Mellitus Screening'		
recommendation		
recommendation		
Human Immune-Deficiency	36415, 86689, 86701,	Payable when billed with a diagnosis in Diagnosis
Virus Counseling &	86702, 86703, 87389,	List 1
Screening	87390, 87391, 87806,	
ou coming	G0432, G0433,	
HRSA Recommendation	G0435, G0475	
December 2016	00 133, 00 173	
The Women's Preventive		
Services Initiative		
recommends prevention		
education and risk		
assessment for human		
immunodeficiency virus (HIV)		
infection in adolescents and		
women at least annually		
throughout the lifespan. All		
women should be tested for		
HIV at least once during their		
lifetime. Additional screening		
should be based on risk, and		
screening annually or more		
often may be appropriate for		
adolescents and women with an increased risk of HIV		
infection. Screening for HIV is		
recommended for all		
pregnant women upon		
initiation of prenatal care		
with retesting during		
pregnancy based on risk		
factors. Rapid HIV testing is		
recommended for pregnant		
women who present in		
active labor with an		

undocumented HIV status.		
Screening during pregnancy		
enables prevention of		
vertical transmission.		
vertical transmission.		
Defended to USDSTE's		
Refer also to USPSTF's		
'Human Immunodeficiency		
Virus (HIV) Infection		
Screening for Pregnant and		
Non-Pregnant Adolescents		
and Adults' recommendation		
Refer also to Bright Future's		
'STI/HIV' Screening'		
recommendations		
Human Papillomavirus	87623, 87624, 87625,	Payable with a diagnosis in Diagnosis List 1
Testing (HPV)	G0476, 0500T	Tayable With a diagnosis in Diagnosis List 1
resting (in v)	00470,03001	
HRSA Recommendation		
August 2012		
HRSA recommends high-risk		
human papillomavirus DNA		
testing in women with		
normal cytology results.		
Screening should begin at 30		
years of age and should		
occur no more frequently		
than every 3 years		
Interpersonal and Domestic	99401, 99402, 99403,	
Violence Screening	99404, 99411, 99412,	
	99384, 99385, 99386,	
HRSA Recommendation	99387, 99394, 99395,	
December 2016	99396, 99397, 99201,	
The Women's Preventive	99202, 99203, 99204,	
Services Initiative	99205, 99211, 99212,	
recommends screening	99213, 99214, 99215	
	73413, 33414, 33413	
adolescents and women for		
interpersonal and domestic		
violence at least annually,		
and, when needed, providing		
or referring for initial		
intervention services.		
Interpersonal and domestic		
violence includes physical		
violence, sexual violence,		
stalking and psychological		

aggression (including		
coercion), reproductive		
coercion, neglect, and the		
threat of violence, abuse, or		
both. Intervention services		
include, but are not limited		
to, counseling, education,		
harm reduction strategies,		
and referral to appropriate		
supportive services.		
Sexually Transmitted	99401, 99402, 99403,	
Infections Counseling	99404, 99411, 99412,	
	99384, 99385, 99386,	
HRSA Recommendation	99387, 99394, 99395,	
December 2016	99396, 99397, G0445	
The Women's Preventive	, 55550, 55551, QU <del>44</del> 5	
Services Initiative		
recommends directed		
behavioral counseling by a		
health care provider or other		
appropriately trained		
individual for sexually active		
adolescent and adult women		
at an increased risk for		
sexually transmitted		
infections (STIs). The		
Women's Preventive		
Services Initiative		
recommends that health		
care providers use a		
woman's sexual history and		
risk factors to help identify		
those at an increased risk of		
STIs. Risk factors may include		
age younger than 25, a		
recent history of an STI, a		
new sex partner, multiple		
partners, a partner with		
concurrent partners, a		
partner with an STI, and a		
lack of or inconsistent		
condom use. For adolescents		
and women not identified as		
high risk, counseling to		
reduce the risk of STIs should		
be considered, as		
determined by clinical		
	l .	

	T	
judgement.		
Refer also to USPSTF's		
'Sexually Transmitted		
Infections Behavioral		
Counseling' recommendation		
Counseling recommendation		
Urinary Incontinence	There are no	Payable with a diagnosis in Diagnosis List 1
Screening	procedure codes	
	specific to this	
HRSA Recommendation	service. This service	
December 2017	would be part of the	
The Women's Preventive	preventive office	
Services Initiative	visit.	
recommends screening		
women for urinary		
incontinence annually.		
Screening should ideally		
assess whether women		
experience urinary		
incontinence and whether it		
impacts their activities and		
quality of life.		
Well-Woman Visits	99384, 99385, 99386,	Labs administered as part of a normal pregnancy
	99387, 99394, 99395,	reimbursable at the preventive level when billed
HRSA Recommendation	99396, 99397, G0101,	with a pregnancy diagnosis
December 2016	G0438, G0439,	
The Women's Preventive	99078, 99401, 99402,	
Services Initiative	99403, 99404, 99411,	
recommends that women	99412, 99408, 99409,	
receive at least one	G0396, G0442,	
preventive care visit per year	G0443, G0444	
beginning in adolescence		
and continuing across the		
lifespan to ensure that the		
recommended preventive		
services, including		
preconception, and many		
services necessary for		
prenatal and interconception		
care are obtained. The		
primary purpose of these		
visits should be the delivery		
and coordination of		
recommended preventive		
services as determined by		
age and risk factors.		

## **ACIP Recommendations:**

Service:	Procedure	Additional
	Code(s):	Reimbursement Criteria:
DTaP Vaccine	90696, 90698, 90700, 90702, 90723	
Hepatitis A Vaccine	90632, 90633, 90634, 90636	
Hepatitis B Vaccine	90739, 90740, 90743, 90744, 90746, 90747, 90748	
Haemophilus Influenzae Type B (Hib) Vaccine	90647, 90648	
Human Papillomavirus Vaccine (HPV)	90649, 90650, 90651	Payable with a diagnosis code in Diagnosis List 1
Influenza Vaccine  Measles, Rubella, Congenital Rubella	90630, 90653, 90654, 90655, 90656, 90657, 90658, 90660, 90661,90662, 90666, 90667, 90668, 90672, 90673, 90674 90682, 90685, 90686, 90687, 90688, 90756 Q2034, Q2035, Q2036, Q2037, Q2038, Q2039	
Syndrome, and Mumps (MMR)		
Measles, Mumps, Rubella, and Varicella (MMRV)	90710	

Meningococcal Vaccine	90644, 90733, 90734, 90620, 90621	
Pneumococcal Vaccine	90670, 90732	
Polio Vaccine	90713	
Rotavirus Vaccine	90680, 90681	
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap/Td)	90714, 90715	
Varicella Vaccine	90716	
Zoster (Shingles) Vaccine	90736, 90750	
Immunization Administration	90460, 90461, 90471, 90472, 90473, 90474, 90674, 90749	

## **Bright Futures Recommendations:**

Service:	Procedure	Additional
	Code(s):	Reimbursement Criteria:
Alcohol Use and Drug Use Assessment	99408, 99409	Payable with a diagnosis code in
		Diagnosis List 1
Bright Futures		
Recommends alcohol and drug use		
assessments for adolescents between the		
ages of 11 to 21 years		
	00004	
Cervical Dysplasia Screening	Q0091	Payable with a diagnosis code in
Dright Futures		Diagnosis List 1
Bright Futures		
Recommends cervical dysplasia screening for		
adolescents age 21 years of age		
Critical Congenital Heart Defect Screening	94760	
Bright Futures		
Recommends screening for critical congenital		
heart disease using pulse oximetry for		
newborns after 24 hours of age, before		
discharge from the hospital		
2.55.25.65 // Sin the 1100pitol		

Bright Futures Recommends depression screening for adolescents between the ages of 11 to 21 years  Refer also to USPSTF's 'Depression in Children and Adolescents Screening' recommendation	96110	Payable with a diagnosis code in Diagnosis List 1
Developmental Screening / Autism Screening  Bright Futures Recommends developmental/autism screening for infants and young children between the ages of 9 months and 30 months	96110	Payable with a diagnosis code in Diagnosis List 1
Bright Futures Recommends dyslipidemia screening for children and adolescents between the ages of 24 months and 21 years of age	80061, 82465, 83718, 84478	Payable with a diagnosis code in Diagnosis List 1
Hearing Screening  Bright Futures Recommends hearing screenings for children and adolescents from birth through 21 years of age	92558, 92586, 92567, 92551, V5008	Payable with a diagnosis code in Diagnosis List 1  Procedure code 92586 is for members under 32 days of age
Hematocrit or Hemoglobin  Bright Futures Recommends hematocrit or hemoglobin screening for children and adolescents between the ages of four months and 21 years of age	36415, 36416, 85014, 85018	Payable with a diagnosis code in Diagnosis List 1
HIV Screening	87389, 87390, 87391, 87806, G0432, G0433, G0435	
Lead Screening	36415, 36416, 83655	Payable with a diagnosis code in Diagnosis List 1

	T	
Bright Futures		
Recommends screening children between the		
ages of six months and six years for lead		
Maternal Depression Screening	99384, 99385, 99386,	
	99387, 99394, 99395,	
	99396, 99397, 96127,	
	G0444	
Newborn Bilirubin	82247, 82248	Payable with a diagnosis in
		Diagnosis List 1
Newborn Blood Screening	S3620	Payable with a diagnosis code in
		Diagnosis List 1
Oral Health	99211, 99212, 99188,	Payable with a diagnosis code in
	99381, 99382, 99383,	Diagnosis List 1
Bright Futures	99384	
Recommends oral health risk assessments		
beginning at six months of age		
beginning at six months of age		
Prenatal Visit	99401, 99402, 99403,	Payable with a diagnosis code in
Trended visit	99404	Diagnosis List 1
	33404	Diagnosis List 1
Preventive Medicine Services: New Patients	99381, 99382, 99383,	Payable with a diagnosis code in
	99384, 99385	Diagnosis List 1
Preventive Medicine Services: Established	99391, 99392, 99393,	Payable with a diagnosis code in
Patients	99394, 99395	Diagnosis List 1
STI/HIV Screening	86631, 86632, 86701,	Payable with a diagnosis code in
311/ HIV Screening		_
Duight Futures	86703, 87081, 87110,	Diagnosis List 1
Bright Futures	87210, 87270, 87320,	
Recommends screening for all sexually active	87490, 87491, 87590,	
patients	87591, 87800, 87801,	
- C - L - L - L - L - C - C - C - C - C	87810, 87850, 36415	
Refer also to USPSTF's 'Human		
Immunodeficiency Virus (HIV) Infection		
Screening for Pregnant and Non-Pregnant		
Adolescents and Adults' recommendations		
Refer also to HRSA's 'Sexually Transmitted		
•		
Infections Counseling' recommendation		
Tuberculosis Testing	86580, 99211	Payable with a diagnosis code in
-		Diagnosis List 1
Bright Futures		
Recommends tuberculosis testing if the risk		
assessment is positive		
assessment is positive		

Vision Screening	99173	Payable with a diagnosis code in
		Diagnosis List 1
Bright Futures		
Recommends vision screening for newborns		
through age 21 years		

Many of the services listed above may be performed for indications other than preventive care. In these situations, services may be covered by another provision of the individual's benefit plan and subject to applicable cost sharing.

#### **Diagnosis List 1**

Z00.00	Z00.01	Z00.110	Z00.111	Z00.121	Z00.129	Z0.08	<u>Z01.10</u>	Z01.411	Z01.419	Z02.83
Z11.1	Z11.3	Z11.4	Z11.51	Z12.11	Z12.12	Z12.2	Z12.31	Z12.39	Z12.4	Z12.5
Z13.0	Z13.1	Z13.220	Z13.31	Z13.32	Z13.4	Z13.41	Z13.42	Z13.5	Z13.6	Z13.820
Z23	Z30.011	Z30.012	Z30.013	Z30.014	Z30.015	Z30.016	Z30.017	Z30.018	Z30.019	Z30.02
Z30.09	Z30.40	Z30.41	Z30.42	Z30.430	Z30.431	Z30.432	Z30.433	Z30.44	Z30.45	Z30.46
Z30.49	Z30.8	Z30.9	Z32.2	Z71.41	Z71.51	Z71.6	Z71.7	Z71.82	Z71.83	Z86.32

#### **Breastfeeding Equipment & Supplies**

Non-grandfathered plans provide coverage of manual, electric, and hospital grade breast pumps along with breastfeeding supplies at the preventive level.

Manual breast pumps utilize procedure code E0602 and are available for purchase and covered at the preventive level when obtained In-Network, Out of Network, or from Retail providers. Sales tax is excluded from retail purchases.

Electric breast pumps utilize procedure code E0603 and must be rented or purchased from an In-Network provider or a contracted durable medical equipment supplier. The models of breast pumps being provided at the preventive level are up to the individual provider's discretion. If a member chooses to obtain an upgraded model, they may be balance billed the difference between the allowance of the standard model and the cost of the upgraded model. Members are allowed one electric breast pump per benefit period.

\*Note: Retail providers such as Babies 'R' Us, Target, Wal-Mart, or online vendor are not licensed medical providers and therefore are considered Out of Network. Out of network coverage will follow the out of network benefit level for preventive services. This may include cost sharing and sales tax is excluded. \*

Hospital grade breast pumps utilize procedure code E0604 and are only covered when rented In-Network or from an In-Network durable medical equipment supplier. Hospital grade breast pump coverage is up to the purchase price of \$1,000.00 or 12 months, whichever comes first. At the end of coverage, the unit must be returned to the durable medical equipment supplier. Members are allowed one breast pump per benefit period.

Breast pumps obtained from Out of Network providers are reimbursable at the Out of Network level.

The following breast pump supplies are reimbursable the preventive level. Some limitations and restrictions may apply based on the group coverage for preventive services.

- A4281- Tubing for breast pump, replacement, spare membranes, replacements
- A4282- Adapter for breast pump, replacement
- A4283- Cap for breast pump bottle, replacement
- A4284- Breast shield and splash protector for use with breast pump, replacement
- A4285- Polycarbonate bottle for use with breast pump, replacement
- A4286- Locking ring for breast pump, replacement

#### <u>Differentiating Preventive Care versus Diagnostic Care</u>

The following types of services are considered Preventive:

- Screenings intended to prevent illness or identify issues before symptoms are evident
- Counseling intervention as defined by a specific preventive recommendation

#### Examples of preventive services:

- A 60-year-old woman obtains her biennial mammogram to screen for breast cancer
- A patient who has been identified as having cardiovascular disease risk factors is referred for nutritional counseling
- A 50-year old patient obtains a colonoscopy to screen for colorectal cancer
- A 42-year-old patient goes to their doctor for their annual physical and receives a blood test to screen for abnormal blood glucose

The following types of services are considered Diagnostic:

- The diagnosis of existing symptoms or abnormalities
- Treatment for specific health conditions, ongoing care, or other tests to manage a health condition

### Examples of diagnostic services:

- A 60-year-old woman obtains a mammogram after noticing a lump in her breast
- A patient diagnosed with diabetes is referred for nutritional counseling to manage their condition

• A patient goes to their doctor for their annual physical and receives a blood test to check iron and liver function, and a urinalysis is requested

#### **Limitations and Exclusions**

- 1. <u>Services not reimbursable at the preventive level may be reimbursable under another portion of</u> the medical plan.
- 2. Breastfeeding equipment and supplies not listed underneath the "Breastfeeding Equipment and Supplies" section. This includes, but is not limited to
  - a. Batteries
  - b. Breastfeeding ointments, creams
  - c. Breast milk storage supplies including bags, freezer packs, etc.
  - d. Breast pump cleaning supplies
  - e. Breast pump traveling cases
  - f. Infant scales
  - g. Nursing bras
  - h. Nursing covers, scarfs
- 3. Immunizations that are not published in the Center for Disease Control's Morbidity and Mortality Weekly Report (MMWR) and/or are not on the list of "Vaccines Licensed for Use in the United States" by the United States Food and Drug Administration (FDA).
- 4. Prescription coverage may vary depending on the terms and conditions of the plans. A prescription may be required for coverage under the pharmacy benefit. The plan may also require that the generic drug be tried first before the brand version. Age limits, restrictions, and other requirements may apply. Members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
- 5. For OTC purchases, members will need to obtain a prescription from their provider and take it to the pharmacy to be filled.
- 6. If there is a medication not included, the member should consult their doctor for therapeutic alternatives first before submitting coverage exceptions to BCBS.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a MEDICAL POLICY and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

#### **References:**

Advisory Committee on Immunization Practices (ACIP). "Vaccine-Specific ACIP Recommendations." (2018, January 26). Retrieved June 26, 2018, from https://www.cdc.gov/vaccines/hcp/acip-recs/index.html

American Academy of Pediatrics- Bright Futures. "Coding for Pediatric Preventive Care, 2018." Retrieved June 26, 2018, from

https://brightfutures.aap.org/Bright%20Futures%20Documents/CodingPedPreventiveCare\_2018.pdf

American Academy of Pediatrics- Bright Futures. "Recommendations for Preventive Pediatric Health Care." (2017, February 1). Retrieved June 26, 2018, from https://www.aap.org/en-us/Documents/periodicity\_schedule.pdf

American Academy of Pediatrics- Bright Futures. "Achieving Bright Futures." Retrieved June 26, 2018 from https://www.aap.org/en-us/Documents/practicet\_periodicity\_AllVisits.pdf

Centers for Disease Control and Prevention. "Immunization Schedules." (2018, February 6). Retrieved June 26m 2018, from https://www.cdc.gov/vaccines/schedules/index.html

Health Resources and Services Administration. "Women's Preventive Services Guidelines." (2017, October 1). Retrieved June 26, 2018, from https://www.hrsa.gov/womens-guidelines-2016/index.html

United States Food and Drug Administration. "Vaccines Licensed for Use in the United States." (2018, March 29). Retrieved June 26, 2018, from

https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833

United States Preventive Services Task Force. "Published Recommendations." (2018, June 1). Retrieved June 26, 2018, from <a href="https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations">https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations</a>

# **Policy update History:**

СРСР	Title	Description	HCSC Approval Date	BCBS-NM Approval Date	Effective Date	End Date
006	Preventative Services Policy	Coding and USPSTF Updates	12/27/2018	1/15/2019	2/1/2019	
006	Preventative Services Policy	Coding and USPSTF Updates	7/12/2018		9/7/2018	1/31/2019
006	Preventative Services Policy	Coding and USPSTF Updates	4/30/2018		5/15/2018	9/6/2018
006	Preventative Services Policy	Coding and USPSTF Updates	12/6/2017		1/22/2018	5/14/2018
006	Preventative Services Policy	Removed codes 99174 and 99177	7/14/2017		8/23/2017	1/21/2018
006	Preventative Services Policy	New Policy	6/23/2017			

The Plan makes no endorsement, representations or warranties regarding any products or services offered by independent third-party vendors such as Babies 'R' Us, Target and Wal-Mart. These vendors are solely responsible for the products and services they offer. If you have any questions about the products or services offered by such vendors, you should contact the vendor(s) directly.